Altered Interactions between the A1 and A2 Subunits of Factor VIIIa following Cleavage of A1 Subunit by Factor Xa*

Keiji NogamiDagger , Hironao WakabayashiDagger , Kyla SchmidtDagger , and Philip J. FayDagger §

From the Departments of Dagger  Biochemistry and Biophysics and § Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642

Received for publication, September 24, 2002, and in revised form, November 6, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Factor VIIIa consists of subunits designated A1, A2, and A3-C1-C2. The limited cofactor activity observed with the isolated A2 subunit is markedly enhanced by the A1 subunit. A truncated A1 (A1336) was previously shown to possess similar affinity for A2 and retain ~60% of its A2 stimulatory activity. We now identify a second site in A1 at Lys36 that is cleaved by factor Xa. A1 truncated at both cleavage sites (A137-336) showed little if any affinity for A2 (Kd>2 µM), whereas factor VIIIa reconstituted with A2 plus A137-336/A3-C1-C2 dimer demonstrated significant cofactor activity (~30% that of factor VIIIa reconstituted with native A1) in a factor Xa generation assay. These affinity values were consistent with values obtained by fluorescence energy transfer using acrylodan-labeled A2 and fluorescein-labeled A1. In contrast, factor VIIIa reconstituted with A137-336 showed little activity in a one-stage clotting assay. This resulted in part from a 5-fold increase in Km for factor X when A1 was cleaved at Arg336. These findings suggest that both A1 termini are necessary for functional interaction of A1 with A2. Furthermore, the C terminus of A1 contributes to the Km for factor X binding to factor Xase, and this parameter is critical for activity assessed in plasma-based assays.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Factor VIII, a plasma protein that participates in the blood coagulation cascade, is deficient or defective in individuals with hemophilia A. Factor VIII functions as a cofactor for the serine protease, factor IXa, in the anionic phospholipid surface-dependent conversion of factor X to Xa. Factor VIII is synthesized as a multi-domain, single chain molecule (A1-A2-B-A3-C1-C2) (1) with a molecular mass of ~300 kDa (2, 3). Factor VIII is processed to a series of divalent metal ion-linked heterodimers by cleavage at the B-A3 junction, generating a heavy chain consisting of the A1-A2-B domains and a light chain consisting of the A3-C1-C2 domains. This procofactor is activated by cleavage at Arg372, Arg740, and Arg1689 by thrombin and factor Xa, converting the dimer into the factor VIIIa trimer composed of the A1, A2, and A3-C1-C2 subunits (4, 5). The resulting factor VIIIa heterotrimer retains the metal ion-dependent linkage between the A1 and A3-C1-C2 subunits, whereas A2 is associated with a weak affinity by electrostatic interactions (5, 6). Factor VIIIa is unstable, and loss of activity is due to the dissociation of the A2 subunit from the A1/A3-C1-C2 dimer (5-7). Under physiological conditions, the Kd for this interaction is ~260 nM (8, 9); however, at slightly acidic pH and low ionic strength, this interaction is facilitated by an ~10-fold increase in the affinity (Kd = ~30 nM) (8).

The role of factor VIIIa in the intrinsic factor Xase is to bind factor IXa, which increases the kcat for factor Xa formation by several orders of magnitude compared with factor IXa alone (10). Interactive sites for factor IXa are localized to A2 and A3 domains (11-13). Recent studies have shown that modulation of factor IXa by the isolated A2 subunit enhances the kcat for factor Xa activation by ~100-fold (14) and that the isolated A1 subunit synergizes this effect (>15-fold) to alter the interaction of A2 subunit with the protease (15, 16).

Early evidence suggested that the C-terminal acidic region of A1 subunit (residues 337-372) represented an A2-interactive site and participated in A2 retention following thrombin activation (17). This region is also implicated in the binding of factor X (18), although the significance of this cofactor-substrate interaction is not well understood. The A1 subunit is cleaved at Arg336 by activated protein C (19), factor IXa (20, 21), and factor Xa (19). Proteolysis at this site correlates with inactivation of factor VIIIa. Thus, this cleavage is thought to represent a mechanism for the dampening of factor Xase activity. A recent study demonstrated that a truncated subunit lacking the C terminus of A1 (A1336) possessed similar affinity for A2 subunit and retained ~60% of the A2 stimulatory activity compared with native A1 (16). However, that study also suggested that the C-terminal region of A1 appeared critical for proper orientation of A2 subunit in factor VIIIa relative to factor IXa (16).

In this study, we examine the intersubunit interactions of factor VIIIa employing a purified A1 subunit form possessing a newly identified cleavage site and designated as A137-336, following cleavage at both termini (Lys36 and Arg336) by factor Xa. These results demonstrate a role for the N terminus of the A1 subunit in preserving a conformation of the subunit necessary for functional interaction with the A2 subunit. Furthermore, these results define a role for the A1 C-terminal region in contributing to the Km for substrate factor X binding to factor Xase. Thus, specific mechanisms for the loss of factor VIIIa function and down-regulation of factor Xase can now be attributed to individual cleavages of the A1 subunit by factor Xa.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents-- Purified recombinant factor VIII preparations were generous gifts from Bayer Corp. (Berkeley, CA) and the Genetics Institute (Cambridge, MA). The monoclonal antibody 58.12 recognizing the N-terminal end of A1 (22) was a gift from Dr. James Brown, and monoclonal antibody C5 recognizing the C-terminal of A1 (23) was a gift from Drs. Carol Fulcher and Zaverio Ruggeri. Phospholipid vesicles containing 20% PS,1 40% PC, and 40% PE (Sigma) were prepared using N-octylglucoside (24). TAP was a gift from Dr. S. Krishnaswamy. The reagents human alpha -thrombin, factor IXa, factor X, and factor Xa (Enzyme Research Laboratories, South Bend, IN) and the chromogenic Xa substrate S-2765 (N-alpha -benzyloxycarbonyl-D-arginyl-glycyl-L-arginyl-p-nitroanilide-dihydrochloride; DiaPharm Group, Westchester, OH) were purchased from the indicated vendors. Acrylodan and fluorescein-5-maleimide were obtained from Molecular Probes (Eugene, OR).

Isolation of Factor VIII Subunits-- Each factor VIII subunit was isolated from recombinant factor VIII. Factor VIII (1.5 µM) was treated overnight at 4 °C in buffer containing 10 mM MES, pH 6.0, 0.25 M NaCl, 50 mM EDTA, and 0.01% Tween 20, and the light chain and heavy chain were isolated following chromatography on SP-Sepharose and Q-Sepharose columns (Amersham Biosciences) as previously described (25). The purified heavy chain was cleaved by thrombin, and the A2 and A1 subunits were purified by fast protein liquid chromatography using a Hi-Trap Heparin column and a Mono-Q column as reported previously (16). The A3-C1-C2 subunit was prepared as previously described (18). The A1/A3-C1-C2 dimer was isolated from thrombin-treated factor VIIIa using a Mono-S column chromatography, and residual A2 subunit was removed using an anti-A2 subunit monoclonal antibody coupled to Affi-Gel 10. The A3-C1-C2 subunit was further purified following dissociation of dimer by EDTA and chromatography on Mono-Q (8). SDS-PAGE of the isolated subunits showed >95% purity. The protein concentrations were determined by the method of Bradford (26).

Cleavage of A1 by Factor Xa to Form A137-336-- Human factor Xa was added to the purified A1 (11 µM) in a 1:10 (mol/mol) ratio in a buffer containing 20 mM HEPES, pH 7.2, 0.1 M NaCl, 5 mM CaCl2, and 0.01% Tween 20 and reacted overnight at 22 °C. The reaction was quenched using TAP at an ~5-fold molar excess relative to factor Xa. The cleaved A1 subunit was fractionated by fast protein liquid chromatography using a Pharmacia Hi-Trap chelating column (1.0 ml), to which 100 µl of 0.1 M CuCl2 was added beforehand (27). The truncated A1 subunit was eluted at 0.2-0.3 M glycine using a linear glycine gradient (0-1.0 M) in 20 mM HEPES, pH 7.2, 0.3 M NaCl, and 0.01% Tween 20. The purity of truncated A1 subunit (A137-336) was >95% as determined by SDS-PAGE. A chromogenic assay revealed <0.1% residual factor Xa activity or TAP present in the purified A137-336. A truncated A1336 subunit was prepared as described earlier (16).

Labeling of A1 and A2 Subunits-- To obtain fluorescein-labeled A1 (Fl-A1) or A137-336, purified A1 (20 µM) or A137-336 (6.5 µM) subunits in 20 mM HEPES, pH 7.2, 100 mM NaCl, 1 mM CaCl2, and 0.01% Tween 20 were reacted with a 50-fold molar excess of fluorescein 5-maleimide in the dark at 22 °C for 4 h. The unbound fluorescein 5-maleimide was removed by dialyzing the reaction mixture at 4 °C overnight in the above buffer. Acrylodan-labeled A2 (Ac-A2) was obtained from reacting factor VIII (1.5 µM) in the above buffer with a 10-fold molar excess of acrylodan. Labeling conditions and removal of unbound acrylodan were as described above. Isolated Ac-A2 subunit was purified from labeled, EDTA-treated factor VIII following thrombin cleavage using the combination of SP-Sepharose, Q-Sepharose, and Hi-Trap heparin chromatography steps as described above. Approximately 0.9-1.1 mol of fluorescein 5-maleimide was incorporated/mol of A1 or A137-336 subunit. The incorporation of acrylodan into A2 subunit was 1.0-1.2 mol/subunit.

Reconstitution of Factor VIIIa Activity-- The A1/A3-C1-C2 dimer was reconstituted with 500 nM A3-C1-C2 and variable levels of A1 form overnight at 4 °C in 20 mM HEPES, pH 7.2, 0.3 M NaCl, 25 mM CaCl2, and 0.01% Tween 20. The dimer solution was diluted 10-fold, and factor VIIIa was formed by the addition of 20 nM A2 subunit in 20 mM MES, pH 6.0, 100 µg/ml bovine serum albumin, and 0.01% Tween 20. The reconstitution reactions were run at 22 °C, and the resulting factor VIIIa activity was determined after 15 min by a one-stage clotting assay using factor VIII-deficient plasma (28).

Factor Xa Generation Assays-- The rate of conversion of factor X to factor Xa was monitored in a purified system (29). For assays examining the stimulation of isolated A2 subunit by A1 subunit forms, 400 nM A2 subunit was first reacted with variable levels of A1 form for 15 min followed by incubation with 5 nM factor IXa and 10 µM PS-PC-PE vesicle in the presence of 20 mM HEPES, pH 7.2, 50 mM NaCl, 5 mM CaCl2, 100 µg/ml bovine serum albumin, and 0.01% Tween 20 for 10 min. For assays examining factor VIIIa reconstitution from A2 subunit plus A1/A3-C1-C2 dimers comprised of different forms of A1, the dimers and 20 nM A2 subunit were reconstituted and incubated with 20 nM factor IXa and 10 µM PS-PC-PE vesicle for 30 s in the above buffer. The reactions for either assay were initiated with the addition of 500 nM factor X. The aliquots were removed at appropriate times to assess initial rates of product formation and added to tubes containing EDTA (final concentration, 50 mM) to stop the reaction. The rates of factor Xa generation were determined by the addition of the chromogenic substrate, S-2765 (final concentration, 0.46 mM). The reactions were read at 405 nm using a Vmax microtiter plate reader (Molecular Devices, Sunnyvale, CA). All of the reactions were run at 22 °C.

Fluorescence Energy Transfer-- Fl-A1/A3-C1-C2 or Fl-A137-336/A3-C1-C2 dimer was formed by reacting 2 µM A3-C1-C2 and 2 µM Fl-A1 or Fl-A137-336 as described above. Ac-A2 (100 or 200 nM) was reconstituted with varying amounts of the dimer or isolated Fl-A1 subunit forms for 30 min at 22 °C in 20 mM MES, pH 6.0, 0.01% Tween 20, and 200 µg/ml bovine serum albumin. Fluorescence measurements were conducted using an Amico-Bowman Series 2 Luminescence Spectrometer (Thermo Spectronic, Rochester, NY). The reconstitution reactions were excited at 395 nm, and emission spectra were monitored at 420-550 nm. Emission scans were run at 3 nm/s in triplicate, and the average values of the spectra were recorded. All of the spectra were corrected for background fluorescence resulting from the reaction buffer and the fluorescein-labeled dimer or Fl-A1 form. The percentage of donor quenching was calculated from integrated fluorescence intensities at lambda  = 460-480 nm.

Electrophoresis and Western Blotting-- SDS-PAGE was performed on a 8% gel using the procedure of Laemmli (30). Electrophoresis was carried out using a Bio-Rad minigel apparatus at 150 V for 1 h. The bands were visualized following staining with GelCode Blue Stain Regent (Pierce). Alternatively, the protein was transferred to a polyvinylidene difluoride membrane using a Bio-Rad mini-transblot apparatus at 50 V for 2 h in buffer containing 10 mM CAPS, pH 11, and 10% (v/v) methanol. The protein was probed using the 58.12 and C5 monoclonal antibodies followed by goat anti-mouse alkaline phosphatase-linked secondary antibody. The signal was detected using the ECF system (Amersham Biosciences), and the blots were scanned at 570 nm using Storm 860 (Molecular Devices).

NH2-terminal Sequence Analysis-- N-terminal sequence analysis of the factor Xa-cleaved A1 subunit was performed using an Applied BioSystems Procise Sequenator by the Protein Sequencing Facility at Cornell University. The subunit was blotted onto polyvinylidene difluoride and stained with Ponceau S, and the band was excised. The sample was subjected to 10 cycles of sequencing.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Isolation and Purification of Factor Xa-cleaved A1 Subunit-- Factor Xa cleaves the A1 subunit (residues 1-372) of human factor VIIIa at Arg336 yielding a truncated subunit lacking the C-terminal domain rich in acidic amino acids (19). Because this cleavage inactivates cofactor activity, an examination of the A1-associated activities following interaction of the isolated subunit with factor Xa was undertaken. We observed that an extended interaction of the subunit with protease (10:1 molar ratio) converted A1 into a subunit of ~40 kDa, which was significantly smaller than the A1 subunit truncated at Arg336 (~45 kDa). Pretreatment of factor Xa with a molar excess of TAP resulted in no generation of either fragment, indicating that both cleavages were catalyzed by factor Xa (results not shown).

Purification of this fragment was problematic because it did not bind to either Mono S or Mono Q columns under low salt conditions. However, it was adsorbed by a Cu2+-bound Hi-Trap chelating column utilizing the copper binding of His residues (27) and was eluted quantitatively and with high purity (>95%) with 0.2-0.3 M glycine. Fig. 1A shows gel electrophoresis of A1, A1336, and the ~40-kDa subunit. A chromogenic assay revealed <0.1% residual factor Xa activity or TAP (used to inactivate the factor Xa) present in the purified fraction. This fragment was further characterized by Western blot analysis, which employed anti-A1 domain monoclonal antibodies specific for the N- and C-terminal sequences. Although native A1 and A1336 subunits were reactive with monoclonal antibody 58.12 (an antibody directed to residues 1-12 of the A1 sequence), the 40-kDa A1 was not identified (Fig. 1B, left panel). Use of the C5 antibody (specific for residues contained with 337-372) showed reactivity with the native A1 subunit only and did not react with either the 40-kDa A1 form or A1336 (Fig. 1B, right panel). These findings indicated that the 40-kDa A1 subunit was truncated at both termini.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   SDS-PAGE and Western blots of native and cleaved A1 forms. A, the purified subunits were run on an 8% gel followed by staining with GelCode Blue. Lane 1, molecular mass markers; lane 2, native A1 subunit; lane 3, A1336; lane 4, A137-336. B, Western blot of the A1 (lane 1), A1336 (lane 2), and A137-336 (lane 3) using anti-A1 monoclonal antibody specific for the N-terminal region (58.12, left panel) and for the C-terminal region (C5, right panel).

Identification of the N-terminal Cleavage Site-- To identify the site of cleavage that results in the N-terminal truncation, the ~40-kDa A1 form was subjected to 10 cycles of automated N-terminal sequence analysis (Table I). Results from this analysis indicated that this A1 form was derived from cleavage at Lys36-Ser37. Thus, cleavage at this site was consistent with no reactivity using the monoclonal antibody specific for the A1 N terminus. This 40-kDa A1 subunit was designated as A137-336. Interestingly, the residue specified at cycle number 5 (Asn41) was not identified. Because this Asn is contained within the N-X-(T/S) N-linked glycosylation site consensus sequence (31), failure to identify this residue provides direct support for utilization of Asn41 for N-linked glycosylation.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Amino-terminal sequence analysis of the ~40-kDa A1 subunit

Stimulation of A2 by A1 Forms-- We previously demonstrated that the isolated A2 subunit possesses limited cofactor activity in stimulating factor IXa-catalyzed activation of factor X (14), and this activity is markedly enhanced in the presence of A1 subunit (15, 16). To gain insights into critical regions of A1 required for this stimulation of A2, the cofactor activity of A2 in the presence of the native form and the two truncated A1 forms were compared using a factor Xa generation assay. Variable levels of A1 forms and 400 nM A2 subunit were combined, and the reactions were initiated by the addition of 5 nM factor IXa and 500 nM factor X as described under "Materials and Methods." The results for the stimulation of A2 by each A1 form are shown in Fig. 2 and Table II. Negligible levels of activity were obtained in the absence of A2 (data not shown) and were corrected for prior to curve fitting. Similar to the recent observations of Koszelak Rosenblum et al. (16), the A1336 subunit stimulated A2 activity to ~60% the level observed for native A1, whereas similar affinities of the two A1 forms for A2 were observed. In contrast, the Vmax value obtained for A137-336 subunit in stimulating A2 cofactor activity (~0.3 min-1) was only slightly greater than the value obtained with A2 subunit alone (~0.1 min-1; data not shown). Although a functional Kd value was difficult to quantitate given the low levels of activity, these data suggest a weak intersubunit interaction for this A1 form with A2 (Kd > 2 µM), consistent with a marked reduction in the capacity of A137-336 to bind A2. Taken together, these results indicate that the N-terminal region of A1 is required for high affinity interaction with A2 subunit and subsequent stimulation of A2 activity.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Stimulation of A2 activity by A1 forms. Cofactor activity of the isolated A2 subunit was measured in a factor Xa generation assay. A2 subunit (400 nM) was reacted with indicated levels of A1 (open circles), A1336 (closed circles), or A137-336 (squares) subunit. After incubation with 5 nM factor IXa and 10 µM PS-PC-PE, the reaction was initiated with the addition of 500 nM factor X as described under "Materials and Methods." The initial rates of factor Xa generation were plotted as functions of A1 concentration and fitted to the quadratic equation by nonlinear least squares regression (45).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Kinetic and binding parameters for interactions of A1 and A2 subunits
The parameter values were calculated by nonlinear least squares regression from the data shown in Figs. 2 and 3 using the formula shown under "Materials and Methods."

Reconstitution of Factor VIIIa Forms-- Although the A137-336 possessed little ability to directly stimulate the A2 subunit, an additional series of experiments was performed to assess the capacity of this A1 form to reconstitute factor VIIIa following association of A3-C1-C2 and A2 subunits. Factor VIIIa was reconstituted in a two-step procedure. In the first step the A1/A3-C1-C2 dimer form was prepared by reacting varying amounts of the A1 forms and 500 nM A3-C1-C2 subunit in the presence of Ca2+ overnight at 4 °C. The resultant dimer solutions were diluted 10-fold and reacted with the A2 subunit (20 nM) to generate the factor VIIIa heterotrimers. Reconstituted factor VIIIa activity was determined in a factor Xa generation assay initiated by the addition of factor IXa (20 nM) and factor X (500 nM) as described under "Materials and Methods." These data are illustrated in Fig. 3 and Table II. The Vmax values obtained at saturating levels of factor VIIIa reconstituted from native A1 and A1336 with A3-C1-C2 plus A2 subunits were 26.9 ± 0.9 and 13.0 ± 0.7 min-1, respectively. These relative activity values were similar to results obtained above for the direct stimulation of the A2 subunit. The Kd value for the intersubunit interaction with A2 using native A1/A3-C1-C2 dimer was 202 ± 21 nM, a value similar to the earlier reported values obtained under physiological conditions (~260 nM) (8, 9). Furthermore, the Kd value (299 ± 51 nM) for A2 subunit interaction with the A1336/A3-C1-C2 dimer was similar to that of native A1.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Factor VIIIa reconstituted with A1 forms. The A1 form/A3-C1-C2 dimer was reconstituted with 500 nM A3-C1-C2 and the indicated levels of A1 (open circles), A1336 (closed circles), or A137-336 (squares) overnight at 4 °C. The reaction was diluted 10-fold, and factor VIIIa was formed by addition of 20 nM A2 subunit. After incubation with 20 nM factor IXa and 10 µM PS-PC-PE, the reaction was initiated with the addition of 500 nM factor X as described under "Materials and Methods." The initial rates of factor Xa generation were plotted as a function of A1 concentration and fitted to the quadratic equation by nonlinear least squares regression.

Interestingly, although isolated A137-336 had little ability to directly stimulate the A2 subunit, likely in part a consequence of a weak affinity interaction for A2, reconstitution of A137-336/A3-C1-C2 dimer plus A2 subunits yielded a form of factor VIIIa that demonstrated significant cofactor activity. This activity (8.0 ± 0.3 min-1) was ~30% the value compared with factor VIIIa formed with native A1 and ~60% of the activity formed with A1336. Furthermore, the A137-336/A3-C1-C2 dimer showed equivalent affinity for the A2 subunit (Kd = 245 ± 35 nM) compared with the values obtained for the native dimer and A1336/A3-C1-C2 dimer. This association of the A137-336 subunit with A3-C1-C2 resulted in a >10-fold affinity enhancement compared with that observed for isolated A137-336 subunit. These results indicate that both a physical and functional interaction of the A137-336 subunit with A2 requires association of this A1 form with the A3-C1-C2 and suggests that this interaction is mediated by an A3-C1-C2-dependent change in the conformation of the A137-336 subunit.

Reconstituted Factor VIIIa Activity Measured in a One-stage Clotting Assay-- Activity of the reconstituted factor VIIIa composed of either native A1 or A137-336 forms was measured in a one-stage clotting assay as described under "Materials and Methods." Compared with factor VIIIa reconstituted with native A1 form, little if any activity was observed for that with the A137-336 form (Fig. 4). This result was in contrast to the results obtained in a factor Xa generation assay with factor VIIIa comprised of the A137-336 form, which yielded ~30% of the activity of factor VIIIa containing native A1. Similarly, we previously reported no activity of factor VIIIa composed of A1336 in a one-stage clotting assay (16), whereas this form showed ~60% of native activity in a factor Xa generation assay in the current study. Thus, the failure to observe factor VIIIa activity with trimer reconstituted from the A137-336 form using a one-stage clotting assay was consistent with the earlier result. Overall these results suggest that the lack of the C-terminal region of A1 leads to disparate results in the two assay systems.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   Activity of reconstituted factor VIIIa forms in a one-stage clotting assay. The A1/A3-C1-C2 (open circles) or A137-336/A3-C1-C2 (closed circles) dimer forms were reconstituted as described in the legend to Fig. 3. The reactions were diluted 10-fold, and factor VIIIa was reconstituted with 20 nM A2 subunit. Cofactor activity was determined in a one-stage clotting assay using factor VIII-deficient plasma as described under "Materials and Methods."

Activity of Factor VIIIa Forms at Variable Substrate Concentration-- Because the above results suggest altered activities of the cofactor forms possessing C-terminal truncations in A1 subunit and because this region of factor VIII contains a factor X-interactive site (18), a study was undertaken to evaluate the role of substrate factor X concentration relative to factor VIII function. We hypothesized that an increase in Km for factor X as a result of a C-terminal truncation in factor VIIIa leading to a disrupted interaction with factor X would have a more pronounced effect on the one-stage assay in which the factor X concentration is ~25% the plasma level or ~40 nM compared with the factor Xa generation assay, which uses a concentration of substrate yielding Vmax conditions (29) (500 nM as described under "Materials and Methods").

For this analysis, 500 nM native A1 or A137-336 subunit and A3-C1-C2 subunit were reconstituted as described above. The preformed dimers were diluted 10-fold and reacted with 20 nM A2 subunit, followed by the addition of 20 nM factor IXa. The reactions were initiated using varying amounts of factor X as described under "Materials and Methods." The results of this experiment are shown in Fig. 5. The Vmax values obtained from the fitted curve for factor VIIIa forms composed of native A1 and A137-336 subunits were 21.8 ± 4.1 and 7.2 ± 0.3 min-1, respectively, consistent with the data described above. The Km value for factor X obtained with factor Xase comprised of the A1-containing factor VIIIa (41.3 ± 3.3 nM) was 5-fold lower compared with that for A137-336-containing factor VIIIa (206 ± 19 nM). Overall, these parameters result in a marked reduction in catalytic efficiency (Vmax/Km) for factor Xase composed of the truncated A1 (0.035 min-1 nM-1) compared with native factor Xase (0.53 min-1 nM-1). These results also indicate that for reactions containing the latter factor VIIIa form, the factor X concentration is ~20% the Km value in the one-stage assay. Taken together, these results support a role for the C-terminal region of A1 in factor Xase substrate binding and are consistent with the hypothesis that the disparity observed in the two assays when using C-terminal truncated factor VIIIa forms reflects, in part, a rate-limiting substrate concentration in the plasma-based assay.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   Kinetics of factor VIIIa forms for factor X. A3-C1-C2 (500 nM) was reconstituted with 500 nM A1 (open circles) or A137-336 (closed circles) overnight at 4 °C. Factor VIIIa was formed by incubation of 50 nM dimer form and 20 nM A2. After incubation with 20 nM factor IXa and 10 µM PS-PC-PE, the reactions were initiated with variable levels of factor X as described under "Materials and Methods." The initial rates of factor Xa generation were plotted as a function of factor X concentration, and the data were fitted by nonlinear least squares analysis.

Energy Transfer between Ac-A2 and Fl-A1 Subunit Forms-- In an earlier report, we demonstrated that reconstitution of factor VIIIa using fluorophore-labeled subunits can be assessed and intersubunit affinity can be quantitated by following fluorescence resonance energy transfer (32). A similar approach was undertaken to examine interactions of isolated A2 with the native and truncated A1 subunit forms. The A2 subunit and the A1 subunit forms were labeled with the sulfhydryl-specific probes, acrylodan and fluorescein-5-maleimide, respectively, utilizing the presence of a free cysteine residue in the A1 (Cys310) and A2 (Cys692) domains (33). Because modification of the isolated A2 subunit with acrylodan results in an inactive subunit that failed to yield functional factor VIIIa in a reconstitution assay (32), the Ac-A2 subunit was isolated from acrylodan-labeled intact factor VIII as described under "Materials and Methods." The incorporation of acrylodan into A2 subunit was 1.0-1.2 mol/subunit. Direct labeling of isolated A1 subunit with fluorescein 5-maleimide yielded an active subunit with similar incorporation of fluorescein 5-maleimide into A1 or A137-336 subunit (0.9-1.1 mol/subunit). Reconstitution of the Ac-A2 subunit and Fl-A1 form/A3-C1-C2 dimer retained >80% specific activity compared with factor VIIIa prepared from unlabeled subunits (data not shown).

Fluorescence experiments were conducted at pH 6.0, which enhances the intersubunit affinity (8), using 200 nM Ac-A2 and varying amount levels of the Fl-A1 form as described under "Materials and Methods." The fluorescence emission spectrum of the Ac-A2 subunit (fluorescence donor) overlaps with the excitation spectrum of the Fl-A1 form (fluorescence acceptor). Upon binding of Ac-A2 to the Fl-A1 form, the fluorescence intensity of the acrylodan is quenched, and the extent of this quenching is an indicator of the spatial separation between donor and acceptor fluorophores (34). The relative fluorescence intensities were recorded and integrated at lambda  = 460-480 nm, and percentage of donor quenching was calculated based on the intensity of Ac-A2 in the absence and presence of the Fl-A1 form. These data are shown in Fig. 6 and Table III. Saturable donor quenching (46.1 ± 3.0%) was observed following titration with Fl-A1, indicative of association of Ac-A2 subunit, and these data were used to calculate a Kd value (432 ± 66 nM). This value obtained using the physical assay was equivalent to intersubunit affinity determined using a functional assay (Kd = 428 nM; see Table II). However, little donor quenching was observed for the Ac-A2-Fl-A137-336 subunit pairing (~7%), and this effect was not saturable over the range of acceptor concentrations employed, suggestive of little association of Ac-A2 with the truncated A1. Thus, the affinity values obtained with the physical assay support the functional affinities determined by the factor Xa generation assay and are consistent with a marked increase in Kd (>4-fold) following cleavage of Lys36.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6.   Energy transfer between Fl-A1 form and Ac-A2. Ac-A2 (200 nM) and varying levels of Fl-A1 (open circles) or Fl-A137-336 (closed circles) was reacted for 30 min as described under "Materials and Methods." The emission intensity of Ac-A2 was measured at lambda  = 460-480 nm and recorded in the absence and presence of indicated levels of the Fl-A1 form. % Donor Quenching refers to the fluorescence intensity of Ac-A2 in the presence of the Fl-A1 form relative to that of Ac-A2 alone. Unlabeled A1 had no effect on the fluorescence emission of Ac-A2. The percentage of quenching was plotted as a function of Fl-A1 concentration, and the data were fitted by nonlinear least squares analysis.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Binding affinity and donor quenching parameters derived from energy transfer between F1-A1 and Ac-A2 subunits
The parameter values were calculated by nonlinear least squares regression from the data shown in Figs. 6 and 7 using the formula shown under "Materials and Methods."

Influence of A3-C1-C2 in the Energy Transfer between Ac-A2 and Fl-A1 Subunits-- To further assess the role of the A3-C1-C2 subunit in the inter-A1-A2 interaction, we performed energy transfer analysis between Ac-A2 and the A1/A3-C1-C2 dimer reconstituted from the Fl-A1 subunit forms and A3- C1-C2. Fl-A1/A3-C1-C2 and Fl-A137-336/A3-C1-C2 dimers were formed by reacting 2 µM A3-C1-C2 with 2 µM Fl-A1 or Fl-A137-336, respectively. Ac-A2 (100 nM) was reconstituted with varying amounts of the dimer forms as described under "Materials and Methods," and the results are shown in Fig. 7 and Table III. Donor quenching was observed for either dimer form, indicative of association of Ac-A2 subunit. The levels of the percentage of donor quenching at saturating Fl-labeled dimer consisting of A1 and A137-336 were 55.6 ± 2.5 and 29.9 ± 1.6%, respectively. These results suggest an altered spatial separation between the fluorophores with an apparent closer separation existing for the native subunits. This result is consistent with an altered conformation in the trimer formed with the truncated A1 form that may reflect reduced cofactor activity.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 7.   Energy transfer between Fl-A1 form/A3-C1-C2 dimer and Ac-A2. Fl-A1/A3-C1-C2 or Fl-A137-336/A3-C1-C2 dimer was reconstituted by reacting 2 µM A3-C1-C2 and 2 µM Fl-A1 (open circles) or Fl-A137-336 (closed circles). Ac-A2 (100 nM) was reacted with varying amounts of each dimer for 30 min as described under "Materials and Methods." % Donor Quenching refers to the fluorescence intensity of Ac-A2 reconstituted with the dimer relative to that of Ac-A2 alone. The data were fitted as described above.

The Kd values calculated for interaction of Ac-A2 with Fl-A1/A3-C1-C2 and Fl-A137-336/A3-C1-C2 dimer were similar (72.2 ± 7.8 and 85.2 ± 10.8 nM, respectively) and ~5-fold less when A3-C1-C2 was included. Comparison of binding energy values calculated for the interaction of A2 with native A1 (Kd = 432 nM, 8.7 kcal mol-1) and with A1/A3-C1-C2 (Kd = 72 nM, 9.7 kcal mol-1) indicate that ~90% of the binding energy for A2 association within the factor VIIIa heterotrimer is derived from interaction with the A1 subunit. Furthermore, the N- and C-terminal truncations in A1 contribute little to the direct binding of A2 in the factor VIIIa heterotrimer. Therefore, the lack of interaction of A2 with the isolated A137-336 compared with high affinity binding of A2 to the dimer containing these A1 truncations suggest that interactions within the dimer promote a change in conformation in A1, facilitating its interaction with A2.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Factor Xa, a potent activator of factor VIII (35), has been shown to cleave human factor VIII at sites identical to those attacked by thrombin during cofactor activation. Factor Xa also attacks Arg1721 in the A3 domain of the A3-C1-C2 subunit and has been shown to cleave the C-terminal region of A1 at a site tentatively identified as Arg336 (19). Earlier studies employing a factor VIII light chain cleaved by factor IXa at Arg1721 showed that cleavage at this site was benign to cofactor function following reconstitution of factor VIII with native heavy chain (7). However, cleavage at Arg336, a site also attacked by activated protein C (19, 36) and factor IXa (20, 21), correlates with inactivation of the cofactor and down-regulation of factor Xase activity. The mechanisms for activity loss following cleavage at Arg336 are not fully understood but include reduced interaction of factor VIIIa with substrate factor X (37) and altered interaction with A2 subunit, as evidenced by reduced stimulation of activity associated with the A2 subunit (16). Thus, subsequent proteolytic attack of the cofactor by generated factor Xa would yield a reaction product limiting further factor Xa generation by a self-dampening mechanism.

In this work we examined the intersubunit interactions of factor VIIIa employing an A1 subunit form following terminal digest with factor Xa. Electrophoretic analysis of a terminal A1 cleavage fragment revealed truncation at its C terminus consistent with the loss of residues 337-372, as well as cleavage at a second prominent factor Xa-catalyzed site at Lys36-Ser37 as determined by N-terminal sequence analysis. The resultant A137-336, truncated by 36 residues at both its termini, showed markedly reduced affinity for the A2 subunit and no apparent capacity to stimulate the limited cofactor activity associated with A2 subunit. This result is in contrast to observations in this report as well as an earlier study (16) using an A1 subunit truncated only at its C terminus, A1336, which demonstrated similar affinity of this A1 form compared with native A1 for A2 subunit and showed a high level (~60%) of A2 stimulatory activity. Thus, these results identify the N-terminal region of A1 as participating either directly or indirectly in the interaction with A2 subunit.

The results obtained from the energy transfer studies comparing Ac-A2 association with Fl-A1 in the absence or presence of A3-C1-C2 suggest that ~90% of the binding energy for A2 association within the factor VIIIa heterotrimer is derived from direct interaction with the A1 subunit. This result is consistent with earlier studies demonstrating a lack of competition of isolated factor VIII light chain (A3-C1-C2) with the A1/A3-C1-C2 dimer for A2 subunit in a functional, factor VIIIa reconstitution assay (8, 17). This value of 90% may represent a minimum value, because A3-C1-C2 appears to alter the conformation of A1 so as to enhance its interaction with A2. This observation was suggested by the weak (undetermined) affinity of isolated A137-336 for A2 subunit as assessed by the energy transfer assay, whereas association of this truncated subunit with A3-C1-C2 restored a high affinity interaction of A2 with the dimer.

Although the molecular basis for the loss of functional interaction between the isolated A1 and A2 subunits with cleavage at the N-terminal site is not well understood, examination of the homology model (38) indicates that A1 residues Pro25-Phe30 juxtapose the A2 domain and that this interaction may be significant. Specifically, Val26 and Asp27 are separated from A2 residues 537-541 by ~2.5-5 Å. These potential contacts in A2 include Arg541 and Val537, and point mutations at these two sites have been shown to result in hemophilia A (HAMSTeRs data base; europium.csc.mrc.ac.uk). However, no point mutations within this sequence in A1 have been identified to yield a hemophilia phenotype. Thus, we speculate that the first 36 residues of A1 may either directly contact A2 and/or promote a conformation of A1 important to its physical interaction with A2. Interestingly, this effect is somewhat ameliorated in the presence of the A3-C1-C2 subunit. Reconstitution of factor VIIIa using the A137-336 form yielded ~30% of the activity of the cofactor formed with native A1 subunit and ~60% of the activity of the cofactor formed with A1336, truncated only at its C terminus. These results suggested that any putative conformation defect attributed to cleavage at Lys36 is somewhat compensated for following the reassociation of A1 with the A3-C1-C2 dimer. This restoration of cofactor function in the presence of A3-C1-C2 was expected based upon earlier observations employing phospholipid-independent, factor Xa generation assay indicating that A1-A3 contacts subsequently positively influence the interaction of A1 with A2 subunits (39). However, the disparate extents of fluorescence quenching we observed for the acrylodan-labeled A2 subunit by the Fl-A1 and Fl-A137-336 forms in the presence of A3-C1-C2 suggested an altered (increased) interspatial separation of fluorophores in the factor VIIIa form possessing the cleaved A1. We suggest that these changes in conformation are responsible for reduced cofactor activity and reflective of altered interaction between the A1 and A2 subunits.

Although factor Xa generation assays showed the truncated A1 forms retained significant activity following reconstitution reactions to yield factor VIIIa, the one-stage clotting assay failed to report significant activity using these forms of the cofactor. We observed a similar result with the one-stage clotting assay using factor VIIIa reconstituted from the A1336 form in an earlier report (16). We now identify a factor contributing to this assay discrepancy. Kinetic analyses using factor Xa generation show a Km for factor X of ~40 nM using factor Xase composed of native factor VIIIa, whereas this value was increased 5-fold for factor Xase comprised of the C-terminal truncated A1. Because the typical factor Xa generation assay uses concentrations of substrate that yield (near) Vmax reaction rates (29), the rates are independent of the concentration of factor X. However, because the plasma concentration of factor X is ~120 nM and the plasma is diluted 4-fold in the one-stage assay, the limiting amount of substrate factor X (~20% the Km value for factor Xase comprised of the cleaved A1 forms) would markedly depress the rate of factor Xase activity and subsequent clot formation for reactions run using these A1 forms. These results contribute to understanding the basis for cofactor inactivation following cleavage at Arg336 by enzymes such as activated protein C.

The kinetic studies ascribe a role for the A1 C terminus 337-372 in the interaction of factor Xase with substrate factor X. This functional effect is consistent with earlier studies suggesting that this sequence represented a factor X interactive site (18). In a complementary study, zero length cross-linking employing either factor VIIIa or the A1/A3-C1-C2 showed a critical salt bridge between the C-terminal region of A1 and the protease domain of factor X (40). The requirement for the A1 C-terminal region was based upon absence of a cross-linked product using the A1336/A3-C1-C2 dimer form. Interestingly, a region in the protease domain distinct from the activation peptide sequence was identified based upon persistence of the linkage following zymogen activation by the X activator in Russel's viper venom. Thus, we speculate that factor Xa may also interact with the C-terminal region of the A1 subunit. Indeed, attack at Lys36 appears dependent upon an intact C terminus of the A1 subunit, indicating an ordered reaction pathway in factor Xa-catalyzed inactivation of factor VIIIa.2

The study by Parker et al. (41) provides a detailed analysis of the proteolytic activation of porcine factor VIII by factor Xa. In addition to cleavage at the thrombin-susceptible sites Arg372, Arg740, and Arg1689, factor Xa also cleaves at Arg219 within A1 and Arg490 within A2 to yield a pentameric factor VIIIa. Although inactivation of cofactor was not studied in that report, no cleavage at Arg336 was noted. Interestingly, Arg219 in A1 is unique to the pig protein and is a Gln residue at the homologous site in the human, dog, and mouse proteins (42-44). Conversely, the Lys36 cleavage site we report in this study is replaced by Gly (pig and dog) and Thr (mouse) in the animal proteins, indicating that this factor Xa site is restricted to the human factor VIII.

Parker et al. (41) also noted that the catalytic efficiency (kcat/Km) for factor Xase comprised of factor Xa-activated cofactor is severalfold lower than that for factor Xase comprised of thrombin-activated factor VIIIa, a result consistent with an earlier study from that laboratory (35). The reason for this is the combination of an ~3-fold increase in the Km for factor X plus a similar fold decrease in Vmax. These parameters approach the deficiencies in kcat and Km as well as the overall reduced catalytic efficiency (~15-fold) we observed for factor Xase wherein the reconstituted cofactor was altered solely within its A1 subunit. Thus, it is tempting to speculate that cleavage of porcine factor VIIIa at Arg219 in the A1 subunit is primarily responsible for the reduced catalytic efficiency relative to thrombin-activated factor VIIIa as observed by these investigators.

In summary, we show that cleavage of the A1 subunit by factor Xa occurs at two distinct sites, Lys36 and Arg336, which are localized on opposite faces of the A1 domain according the homology model of Pemberton et al. (38). This spatial orientation suggests a complex interaction of protease with this subunit in attack of the scissile bonds. Both cleavages reduce, by degrees, the intrinsic capacity of A1 subunit to stimulate the cofactor activity associated with the A2 subunit. Although the activity loss resulting from cleavage of A1 at Arg336 persists following reconstitution with the A3-C1-C2 subunit, the activity loss attributed to cleavage at Lys36 is somewhat restored upon reassociation in the dimer. This result suggests that a component of the contribution of residues 1-36 is in maintaining an active conformation of the A1 subunit. Importantly, a prominent mechanism for the loss of cofactor activity following terminal digest of the A1 subunit reflects a markedly increased Km for factor X, a property that likely severely limits factor Xase activity in plasma.

    ACKNOWLEDGEMENTS

We thank Debra Pittman of Genetics Institute and Lisa Regan of Bayer Corporation for the gifts of recombinant factor VIII.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HL 38199 and HL 30616.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Biochemistry and Biophysics, P. O. Box 610, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14642. Tel.: 585-275-6576; Fax: 585-473-4314; E-mail: Philip_Fay@urmc.rochester.edu.

Published, JBC Papers in Press, November 7, 2002, DOI 10.1074/jbc.M209811200

2 K. Nogami and P. J. Fay, unpublished observation.

    ABBREVIATIONS

The abbreviations used are: PS, phosphatidylserine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; TAP, tick anticoagulant peptide; MES, 4-morpholineethanesulfonic acid; Ac-A2, A2 subunit labeled with acrylodan; Fl-A1, A1 labeled with fluorescein; Fl-A137-336, A137-336 labeled with fluorescein; CAPS, 3-(cyclo-hexylamino)-1-propanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Vehar, G. A., Keyt, B., Eaton, D., Rodriguez, H., O'Brien, D. P., Rotblat, F., Oppermann, H., Keck, R., Wood, W. I., Harkins, R. N., Tuddenham, E. G. D., Lawn, R. M., and Capon, D. J. (1984) Nature 312, 337-342[Medline] [Order article via Infotrieve]
2. Wood, W. I., Capon, D. J., Simonsen, C. C., Eaton, D. L., Gitschier, J., Keyt, B., Seeburg, P. H., Smith, D. H., Hollingshead, P., Wion, K. L., Delwart, E., Tuddenham, E. D. G., Vehar, G. A., and Lawn, R. M. (1984) Nature 312, 330-337[Medline] [Order article via Infotrieve]
3. Toole, J. J., Knopf, J. L., Wozney, J. M., Sultzman, L. A., Buecker, J. L., Pittman, D. D., Kaufman, R. J., Brown, E., Shoemaker, C., Orr, E. C., Amphlett, G. W., Foster, W. B., Coe, M. L., Knutson, G. J., Fass, D. N., and Hewick, R. M. (1984) Nature 312, 342-347[Medline] [Order article via Infotrieve]
4. Lollar, P., and Parker, C. G. (1989) Biochemistry 28, 666-674[Medline] [Order article via Infotrieve]
5. Fay, P. J., Haidaris, P. J., and Smudzin, T. M. (1991) J. Biol. Chem. 266, 8957-8962[Abstract/Free Full Text]
6. Lollar, P., and Parker, E. T. (1991) J. Biol. Chem. 266, 12481-12486[Abstract/Free Full Text]
7. Fay, P. J., Beattie, T. L., Regan, L. M., O'Brien, L. M., and Kaufman, R. J. (1996) J. Biol. Chem. 271, 6027-6032[Abstract/Free Full Text]
8. Fay, P. J., and Smudzin, T. M. (1992) J. Biol. Chem. 267, 13246-13250[Abstract/Free Full Text]
9. Lollar, P., Parker, E. T., and Fay, P. J. (1992) J. Biol. Chem. 267, 23652-23657[Abstract/Free Full Text]
10. van Dieijen, G., Tans, G., Rosing, J., and Hemker, H. C. (1981) J. Biol. Chem. 256, 3433-3442[Abstract/Free Full Text]
11. Fay, P. J., Beattie, T., Huggins, C. F., and Regan, L. M. (1994) J. Biol. Chem. 269, 20522-20527[Abstract/Free Full Text]
12. Lenting, P. J., Donath, M. J., van Mourik, J. A., and Mertens, K. (1994) J. Biol. Chem. 269, 7150-7155[Abstract/Free Full Text]
13. Bajaj, S. P., Schmidt, A. E., Mathur, A., Padmanabhan, K., Zhong, D., Mastri, M., and Fay, P. J. (2001) J. Biol. Chem. 276, 16302-16309[Abstract/Free Full Text]
14. Fay, P. J., and Koshibu, K. (1998) J. Biol. Chem. 273, 19049-19054[Abstract/Free Full Text]
15. Fay, P. J., Koshibu, K., and Mastri, M. (1999) J. Biol. Chem. 274, 15401-15406[Abstract/Free Full Text]
16. Koszelak Rosenblum, M. E., Schmidt, K., Freas, J., Mastri, M., and Fay, P. J. (2002) J. Biol. Chem. 277, 11664-11669[Abstract/Free Full Text]
17. Fay, P. J., Haidaris, P. J., and Huggins, C. F. (1993) J. Biol. Chem. 268, 17861-17866[Abstract/Free Full Text]
18. Lapan, K. A., and Fay, P. J. (1997) J. Biol. Chem. 272, 2082-2088[Abstract/Free Full Text]
19. Eaton, D., Rodriguez, H., and Vehar, G. A. (1986) Biochemistry 25, 505-512[Medline] [Order article via Infotrieve]
20. O'Brien, D. P., Johnson, D., Byfield, P., and Tuddenham, E. G. (1992) Biochemistry 31, 2805-2812[Medline] [Order article via Infotrieve]
21. Lamphear, B. J., and Fay, P. J. (1992) Blood 80, 3120-3126[Abstract]
22. O'Brien, L. M., Huggins, C. F., and Fay, P. J. (1997) Blood 90, 3943-3950[Abstract/Free Full Text]
23. Foster, P. A., Fulcher, C. A., Houghten, R. A., de Graaf Mahoney, S., and Zimmerman, T. S. (1988) J. Clin. Invest. 82, 123-128[Medline] [Order article via Infotrieve]
24. Mimms, L. T., Zampighi, G., Nozaki, Y., Tanford, C., and Reynolds, J. A. (1981) Biochemistry 20, 833-840[Medline] [Order article via Infotrieve]
25. Fay, P. J., Mastri, M., Koszelak, M. E., and Wakabayashi, H. (2001) J. Biol. Chem. 276, 12434-12439[Abstract/Free Full Text]
26. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
27. Porath, J., Carlsson, J., Olsson, I., and Belfrage, G. (1975) Nature 258, 598-599[Medline] [Order article via Infotrieve]
28. Casillas, G., Simonetti, C., and Pavlovsky, A. (1971) Coagulation 4, 107-111
29. Lollar, P., Fay, P. J., and Fass, D. N. (1993) Methods Enzymol. 222, 128-143[Medline] [Order article via Infotrieve]
30. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
31. Medzihradszky, K. F., Besman, M. J., and Burlingarne, A. L. (1997) Anal. Chem. 69, 3986-3994[CrossRef][Medline] [Order article via Infotrieve]
32. Koszelak, M. E., Huggins, C. F., and Fay, P. J. (2000) J. Biol. Chem. 275, 27137-27144[Abstract/Free Full Text]
33. McMullen, B. A., Fujikawa, K., Davie, E. W., Hedner, U., and Ezban, M. (1995) Protein Sci. 4, 740-746[Abstract/Free Full Text]
34. Lakowicz, J. R. (1983) Principles of Fluorescence Spectroscopy , Plenum, New York
35. Lollar, P., Knutson, G. J., and Fass, D. N. (1985) Biochemistry 24, 8056-8064[Medline] [Order article via Infotrieve]
36. Fay, P. J., Smudzin, T. M., and Walker, F. J. (1991) J. Biol. Chem. 266, 20139-20145[Abstract/Free Full Text]
37. Regan, L. M., O'Brien, L. M., Beattie, T. L., Sudhakar, K., Walker, F. J., and Fay, P. J. (1996) J. Biol. Chem. 271, 3982-3987[Abstract/Free Full Text]
38. Pemberton, S., Lindley, P., Zaitsev, V., Card, G., Tuddenham, E. G. D., and Kemball-Cook, G. (1997) Blood 89, 2413-2421[Abstract/Free Full Text]
39. Fay, P. J., Mastri, M., and Koszelak, M. E. (2001) Biochim. Biophys. Acta 1548, 159-168[Medline] [Order article via Infotrieve]
40. Lapan, K. A., and Fay, P. J. (1998) Thromb. Haemostasis 80, 418-422[Medline] [Order article via Infotrieve]
41. Parker, E. T., Pohl, J., Blackburn, M. N., and Lollar, P. (1997) Biochemistry 36, 9365-9373[CrossRef][Medline] [Order article via Infotrieve]
42. Healey, J. F., Lubin, I. M., and Lollar, P. (1996) Blood 88, 4209-4214[Abstract/Free Full Text]
43. Cameron, C., Notley, C., Hoyle, S., McGlynn, L., Hough, C., Kamisue, S., Giles, A., and Lillicrap, D. (1998) Thromb. Haemostasis 79, 317-322[Medline] [Order article via Infotrieve]
44. Elder, B., Lakich, D., and Gitschier, J. (1993) Genomics 16, 374-379[CrossRef][Medline] [Order article via Infotrieve]
45. Wakabayashi, H., Koszelak, M. E., Mastri, M., and Fay, P. J. (2001) Biochemistry 40, 10293-10300[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.